Aclaris Therapeutics, Inc. (ACRS)

Aclaris Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Revenue	7.83	18.72	31.25	29.75	6.76
Revenue Growth (YoY)	-58.19%	-40.09%	5.03%	340.05%	4.30%
Cost of Revenue	2.09	2.79	3.42	4.02	4.71
Gross Profit	5.74	15.93	27.83	25.73	2.05
Selling, General & Admin	21.97	22.2	32.41	25.13	23.62
Research & Development	52.65	120.49	105.01	77.81	43.81
Other Operating Expenses	7.49	15.17	-12.24	12.64	24.34
Total Operating Expenses	82.11	157.86	125.18	115.58	91.77
Operating Income	-76.38	-141.93	-97.36	-89.85	-89.72
Interest Income	11.45	9.87	8.51	-	-
Other Non-Operating Income (Expense)	-	-	-	2.95	-1.14
Total Non-Operating Income (Expense)	11.45	9.87	8.51	2.95	-1.14
Pretax Income	-64.92	-132.07	-88.85	-86.91	-90.87
Provision for Income Taxes	-	-	-0.37	-	-
Net Income	-64.92	-132.07	-88.48	-86.91	-90.87
Net Income to Common	-64.92	-132.07	-88.48	-86.91	-90.87
Shares Outstanding (Basic)	123	77	70	65	57
Shares Outstanding (Diluted)	123	77	70	65	57
Shares Change (YoY)	58.56%	10.73%	7.05%	14.95%	33.36%
EPS (Basic)	-0.53	-1.71	-1.27	-1.33	-1.60
EPS (Diluted)	-0.53	-1.71	-1.27	-1.33	-1.60
Free Cash Flow	-47.22	-20.2	-79.63	-68.17	-52.44
Free Cash Flow Per Share	-0.39	-0.26	-1.14	-1.05	-0.92
Gross Margin	73.28%	85.09%	89.05%	86.48%	30.29%
Operating Margin	-975.91%	-758.18%	-311.55%	-302.01%	-1327.07%
Profit Margin	-829.58%	-705.48%	-283.15%	-292.11%	-1343.96%
FCF Margin	-603.42%	-107.88%	-254.84%	-229.13%	-775.65%
EBITDA	-75.92	-141.13	-96.49	-89.06	-88.8
EBITDA Margin	-970.11%	-753.87%	-308.79%	-299.33%	-1313.42%
EBIT	-76.38	-141.93	-97.36	-89.85	-89.72
EBIT Margin	-975.91%	-758.18%	-311.55%	-302.01%	-1327.07%
Effective Tax Rate	0.00%	0.00%	0.41%	0.00%	0.00%

Updated Feb 26, 2026. Data Source: Fiscal.ai. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q